Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 50,299 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Malignancies Clear all
Recruiting No phase listed Observational

Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy

NCT04616131
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
3
States / cities
DeKalb, Illinois • Geneva, Illinois • Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 21, 2026, 5:11 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia)

NCT00346502
View directory record Official record
Conditions
Dysplastic Nevus Syndrome
Interventions
20% betulinic acid ointment, BA
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 21, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

NCT03959241
View directory record Official record
Conditions
Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma
Interventions
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate, Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide, Mycophenolate Mofetil, Cyclophosphamide
Procedure · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 21, 2026, 5:11 AM EDT
Completed Not applicable Interventional Results available

Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide

NCT01478854
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Radiation, Chemotherapy
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 21, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)

NCT01201694
View directory record Official record
Conditions
Advanced Cancers
Interventions
Surface-Controlled Water Soluble Curcumin, Surface-Controlled Water Soluble Curcumin MTD
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 21, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

CC-5013 in Treating Patients With Recurrent Glioma

NCT00036894
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
lenalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 21, 2026, 5:11 AM EDT
Active, not recruiting No phase listed Observational

BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy

NCT06335966
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Screening with swallowable esophageal cell-collection devices (SECD)
Device
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
50 Years and older · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 21, 2026, 5:11 AM EDT
Terminated Phase 1 Interventional Results available

Methylphenidate for Cancer-Related Fatigue

NCT01164956
View directory record Official record
Conditions
Cancer
Interventions
methylphenidate, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
7 Years to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 21, 2026, 5:11 AM EDT
Recruiting No phase listed Observational

Natural History Study of Kaposi Sarcoma

NCT06375122
View directory record Official record
Conditions
Kaposi Sarcoma, HIV
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 5:11 AM EDT
Terminated Phase 1 Interventional Results available

Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma

NCT01738594
View directory record Official record
Conditions
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome
Interventions
carfilzomib, romidepsin, laboratory biomarker analysis
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 21, 2026, 5:11 AM EDT
Recruiting Not applicable Interventional

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

NCT05287451
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer
Interventions
RIsk-Reducing Salpingectomy (RRS), Risk-Reducing Oophorectomy-RRO, Risk-Reducing Salpingo-Oophorectomy-RRSO
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

NCT01252251
View directory record Official record
Conditions
Uveal Melanoma
Interventions
RAD001 (Everolimus) and Pasireotide (SOM230) LAR
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 21, 2026, 5:11 AM EDT
Completed No phase listed Observational

Predicting Tolerance to Radiation Therapy in Older Adults With Cancer

NCT01752751
View directory record Official record
Conditions
Pre-treatment Loss of Independent Activities of Daily Living
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 21, 2026, 5:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma

NCT00859222
View directory record Official record
Conditions
Malignant Glioma
Interventions
LBH589, bevacizumab
Drug
Lead sponsor
Patrick Y. Wen, MD
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
Chicago, Illinois • Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 21, 2026, 5:11 AM EDT
Completed No phase listed Observational

Environmental Factors in the Development of Polycystic Ovary Syndrome

NCT00341731
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Research Triangle Park, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 21, 2026, 5:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

NCT03192202
View directory record Official record
Conditions
Lymphoma, T-Cell, Cutaneous
Interventions
AFM13
Drug
Lead sponsor
Ahmed Sawas
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 21, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy

NCT00233402
View directory record Official record
Conditions
Bladder Cancer
Interventions
Hexvix, Standard white light cystoscopy
Drug · Procedure
Lead sponsor
Photocure
Industry
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
15
States / cities
Stanford, California • Gainesville, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Oct 21, 2026, 5:11 AM EDT
Terminated Phase 2 Interventional

Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure

NCT03879629
View directory record Official record
Conditions
Breast Cancer
Interventions
Carvedilol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 21, 2026, 5:11 AM EDT
Terminated Phase 1 Interventional

Vaccine Therapy in Treating Patients With Kidney Cancer

NCT00014131
View directory record Official record
Conditions
Kidney Cancer
Interventions
Biological/Vaccine: therapeutic autologous dendritic cells.
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
16 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 21, 2026, 5:11 AM EDT
Not yet recruiting No phase listed Observational

Patient Reported Outcomes Following Percutaneous Lung Ablation

NCT07720102
View directory record Official record
Conditions
Lung Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 21, 2026, 5:11 AM EDT
Terminated No phase listed Observational

Companion Pharmacogenetic Study to UMCC 9900/9901

NCT00146029
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Not listed
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2008 · Synced Oct 21, 2026, 5:11 AM EDT
Terminated Phase 1 Interventional Results available

PF-06671008 Dose Escalation Study in Advanced Solid Tumors

NCT02659631
View directory record Official record
Conditions
Neoplasms
Interventions
PF-06671008
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Harrison, New York • New York, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 21, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

NCT03139331
View directory record Official record
Conditions
Sarcoma, Refractory Sarcoma
Interventions
Pazopanib, Irinotecan, Temozolomide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Oakland, California • San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 21, 2026, 5:11 AM EDT
Active, not recruiting Phase 2 Interventional

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

NCT03482102
View directory record Official record
Conditions
Hepatocellular Carcinoma, Biliary Tract Cancer
Interventions
Tremelimumab, Durvalumab, Radiation
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 21, 2026, 5:11 AM EDT